The clock is ticking for Ocugen, and the market is counting every second. The biotech group now has a clear European regulatory pathway for its gene therapy OCU400 — the EMA has granted a centralised review procedure and classified it as an advanced therapy medicine. But that bureaucratic progress has done little to jolt a stock that is essentially marking time until the one piece of data that truly matters.
Ocugen shares closed at €1.22, barely above their 50-day moving average of €1.20. Over the past month, the stock has risen 14.42%, but the last seven days have erased 5.42% — evidence of a market that swings on empty calories when no fresh news is on the menu. From its 52-week high of €2.35 set in March, the stock has shed 48% of its value. The annualised 30-day volatility of 65.35% and a relative strength index of 47.3 underline a name that is directionless, paused, and waiting.
That waiting has a specific deadline. Ocugen expects topline Phase 3 data from the liMeliGhT trial for OCU400 — a gene therapy targeting retinitis pigmentosa — in the first quarter of 2027. Final study results are due by year-end 2027. In between, the company plans to start a rolling biologics license application (BLA) with the US Food and Drug Administration in the third quarter of 2026 and complete the filing by the second quarter of 2027. The EMA approval pathway runs in parallel; an EU filing is slated for 2026, with a possible green light in 2027.
To get there, Ocugen has had to shore up its balance sheet more aggressively than originally planned. At the end of 2025, the company held $18.9 million in cash and restricted cash. A $22.5 million financing round in January 2026 was supposed to provide a runway into the fourth quarter of that year — but with the pivotal catalyst still a year away, management opted for more. In May 2026, Ocugen issued convertible notes at 6.75%, due 2034, boosting total cash to roughly $99 million and extending the runway into 2028. The cost: potential dilution. With 312.4 million shares already outstanding, the conversion of the notes and warrants will add to the count. Time bought with equity is never free.
Should investors sell immediately? Or is it worth buying Ocugen?
The analyst consensus target of €9.98 implies a 716% upside from current levels. That number only makes sense if OCU400 clears the Phase 3 hurdle and secures approval. It is not a conventional valuation — it is a wager on a binary event still more than a year away, a scenario the market is not yet pricing in.
Ocugen does have a clinical signal to lean on. In a Phase 1/2 cohort, eight evaluable patients showed a gain of roughly two lines in low-light visual acuity after three years of follow-up. Seven of the eight — 88% — either improved or maintained visual function compared with the untreated eye. These data come from an open-label, uncontrolled cohort and are considered hypothesis-generating rather than proof. Still, they underpin the regulatory momentum.
For now, Ocugen’s stock moves less on fundamentals than on the market’s shifting appetite for patience. The 200-day moving average sits at €1.31, just above the current price — a sign that, despite occasional spikes, the stock has essentially gone nowhere over the past year. With volatility near 66% and a handful of concrete milestones — the BLA start, the Phase 3 readout — still several quarters away, the shares are likely to remain in technical limbo. The real catalyst is not a quarterly earnings beat; it is a single clinical result that the calendar says is still more than half a year off. Until then, Ocugen trades on hope, not data.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from July 17 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 17.
Ocugen: Buy or sell? Read more here...
